- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04060368
Efficacy and Safety of Endoscopic Sleeve Gastroplasty Versus Laparoscopic Sleeve Gastrectomy in Obese Subjects With NASH (TESLA-NASH)
STudy to Evaluate the Efficacy and Safety of Endoscopic Sleeve Gastroplasty (ESG) Versus LAparoscopic Sleeve Gastrectomy (LSG) in Obese Subjects With Non-Alcoholic SteatoHepatitis (NASH)
The primary objectives of this study are to evaluate the effect of ESG with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) compared to LSG on 1) histological improvement in NASH; 2) all-cause mortality and liver-related outcomes In obese subjects with non-alcoholic steatohepatitis (NASH).
Condition or disease: Non-alcoholic steatohepatitis (NASH) with or without fibrosis Intervention/treatment: ESG with OverStitch® system vs LSG
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Javier Crespo, PROF
- Phone Number: +34942204089
- Email: javier.crespo@scsalud.es
Study Contact Backup
- Name: Paula Iruzubieta, MD, PhD
- Phone Number: +34942204089
- Email: p.iruzubieta@gmail.com
Study Locations
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
- Recruiting
- Hospitl Universitario Marqués de Valdecilla
-
Contact:
- Paula Iruzubieta, PHD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects aged between 18 and 60 years (inclusive) at first screening visit.
- Must provide signed written informed consent and agree to comply with the study protocol.
- BMI between 35 and 45 kg/m2 with or without metabolic risk factors (type 2 diabetes, arterial hypertension, dyslipidaemia), and BMI between 30 and 34,9 kg/m2 with type 2 diabetes.
Histological confirmation of steatohepatitis in a diagnostic liver biopsy (biopsy obtained in the 6 months prior to randomization or during the selection period) with at least a score of 1 in each component of the NAS score (steatosis with a score of 0 to 3, degeneration by ballooning with a score of 0 to 2 and lobular inflammation with a score of 0 to 3) and:
- NAS score ≥ 4
- fibrosis < 4 according to the staging system of CRN fibrosis on NASH
- For patients with fibrosis ≤ 1, must be associated at least one of the following conditions: metabolic syndrome (NCEP ATP III definition), type 2 diabetes, HOMA-IR >6
- Absence of other well documented causes of chronic liver disease (alcoholic liver disease, viral hepatitis, cholestasis, autoimmune hepatitis, Wilson's disease, hemochromatosis, alpha 1 antitrypsin deficiency)
- Patients agree to have 1 liver biopsy after 96 weeks after intervention
Exclusion Criteria:
- Known heart failure (Grade I to IV of the classification of the New York Heart Association).
- History of efficient bariatric surgery within 10 years prior to Screening.
- Patients with a history of clinically significant acute cardiac event in the 6 months prior to selection, such as: acute cardiovascular event, cerebrovascular accident, transient ischemic attack, or coronary heart disease (angina pectoris, myocardial infarction, revascularization procedures).
- Weight loss of more than 5% in the 6 months prior to randomization.
- Recent or current background of significant consumption of alcoholic beverages (<5 years). In the case of men, significant consumption is usually defined as more than 30 g of pure alcohol per day. In the case of women, it is usually defined as more than 20 g of pure alcohol per day.
- Liver cirrhosis.
- Non-cirrhotic portal hypertension.
- Esophagogastric varices.
- Hepatocellular carcinoma
- Portal thrombosis.
- Pregnancy.
- Refusal to give informed consent.
- Any medical condition that could reduce life expectancy to less than 2 years, including known cancers.
- Signs of any other unstable or clinically significant immunological, endocrine, hematological, gastrointestinal, neurological, neoplastic or psychiatric disease without treatment.
- Instability or mental incompetence, so that the validity of the informed consent or the ability to comply with the study are uncertain.
- Antibodies positive for the human immunodeficiency virus.
Descompensated liver disease with the following hematologic and biochemical criteria:
- Aspartate aminotransferase (AST) and / or ALT> 10 x upper limit of normal (ULN)
- Total bilirubin> 25 μmol / l (1.5 mg / dl)
- Standardized international index> 1.4
- Platelet count <100 000 / mm3
- Serum creatinine levels> 135 μmol / l (> 1.53 mg / dl) in men and> 110 μmol / l (> 1.24 mg / dl) in women.
- Significant renal disease, including nephritic syndrome, chronic kidney disease (patients with markers of hepatic injury or estimated glomerular filtration rate [eGFR] of less than 60 ml / min / 1.73 m2). If an abnormal value is obtained at the first screening visit, the eGFR measurement may be repeated before randomization within the following time frame: minimum 4 weeks after the initial test and maximum 2 weeks before the expected randomization. An abnormal repeated eGFR (less than 60 ml / min / 1.73 m2) leads to exclusion from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ESG Stitch® system + Lifestyle modifications
Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery.
Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
|
Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery.
Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
|
ACTIVE_COMPARATOR: LSG + Lifestyle modifications
Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
|
Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects undergoing ESG relative to LSG achieving resolution of NASH without worsening of fibrosis
Time Frame: Measurement at 96 weeks
|
To evaluate the effect of ESG compared to LSG on liver histology in obese subjects with NASH with or without fibrosis by assessing the following endpoint: The proportion of subjects undergoing ESG relative to LSG achieving NASH resolution without worsening of fibrosis.
NASH resolution is defined as the disappearance of ballooning and the disappearance or persistence of minimal lobular inflammation (grade 0 or 1) The worsening of fibrosis is defined as the progression of at least one stage.
|
Measurement at 96 weeks
|
Proportion of subjects undergoing ESG relative to LSG with cardiovascular and liver-related death events
Time Frame: Measurement at 96 weeks
|
To evaluate the effect of ESG compared to LSG on liver histology in obese subjects with NASH with fibrosis by assessing the following endpoint: The proportion of subjects undergoing ESG relative to LSG achieving improvement of liver fibrosis of at least one stage.
|
Measurement at 96 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects undergoing ESG relative to LSG achieving improvement in liver histology according to the NASH-CRN scoring
Time Frame: Measurement at 96 weeks
|
Percentage of patients with at least 1 point improvement
|
Measurement at 96 weeks
|
Changes in the liver enzymes
Time Frame: Measurement at 96 weeks
|
ALT, AST, GGT, AP (U/L)
|
Measurement at 96 weeks
|
Changes in lipid parameter
Time Frame: Measurement at 96 weeks
|
Cholesterol, LDL, HDL, Triglycerides (mg/dL)
|
Measurement at 96 weeks
|
Changes in noninvasive markers of fibrosis and steatosis
Time Frame: Measurement at 96 weeks
|
Fatty Liver Index (FLI) (<30; 30-60; >60)
|
Measurement at 96 weeks
|
Changes in noninvasive markers of fibrosis and steatosis
Time Frame: Measurement at 96 weeks
|
Hepatic steatosis index (HSI) (<30; 30-36; >36)
|
Measurement at 96 weeks
|
Changes in noninvasive markers of fibrosis and steatosis
Time Frame: Measurement at 96 weeks
|
NAFLD fibrosis score (NFS) (<-1.455;
-1.455-0.676;
>0.676)
|
Measurement at 96 weeks
|
Changes in noninvasive markers of fibrosis and steatosis
Time Frame: Measurement at 96 weeks
|
AST to Plateler ratio index (APRI) (<1, >1)
|
Measurement at 96 weeks
|
Changes in noninvasive markers of fibrosis and steatosis
Time Frame: Measurement at 96 weeks
|
Fibrosis-4 (FIB-4) (<1.30; 1.30-2.67;
>2.67)
|
Measurement at 96 weeks
|
Changes in noninvasive markers of fibrosis and steatosis
Time Frame: Measurement at 96 weeks
|
Hepamet fibrosis score (HFS) (<0.12; 0.12-0.47;
>0.47)
|
Measurement at 96 weeks
|
Changes in body weight
Time Frame: Measurement at 96 weeks
|
body weight
|
Measurement at 96 weeks
|
Changes in inflammatory markers
Time Frame: Measurement at 96 weeks
|
Ferritin in ng/mL
|
Measurement at 96 weeks
|
Changes in inflammatory markers
Time Frame: Measurement at 96 weeks
|
C-rective protein (CRP) in mg/dL
|
Measurement at 96 weeks
|
Changes in inflammatory markers
Time Frame: Measurement at 96 weeks
|
High sensitivity C-reactive protein (hs-CRP) in mg/L
|
Measurement at 96 weeks
|
Changes in inflammatory markers
Time Frame: Measurement at 96 weeks
|
Interleukin 6 (IL-6) in pg/mL
|
Measurement at 96 weeks
|
Changes in inflammatory markers
Time Frame: Measurement at 96 weeks
|
Interleukin 1 beta (IL-1b) in pg/mL
|
Measurement at 96 weeks
|
Changes in inflammatory markers
Time Frame: Measurement at 96 weeks
|
Tumor necrosis factor alpha (TNFa) in pg/mL
|
Measurement at 96 weeks
|
Changes in serum expression of incretins
Time Frame: Measurement at 96 weeks
|
serum expression of incretins
|
Measurement at 96 weeks
|
Changes in mineral metabolism parameters.
Time Frame: Measurement at 96 weeks
|
Parathormone (PTH) (pg/mL), 25(OH)D (ng/mL), PINP, b-CTX (ng/mL)
|
Measurement at 96 weeks
|
Changes in gut microbiota
Time Frame: Measurement at 96 weeks
|
Analysis using 16S rRNA sequencing from stool samples
|
Measurement at 96 weeks
|
Changes in glucose homeostasis markers and insulin resistance
Time Frame: Measurement at 96 weeks
|
Glucose in mg/dL
|
Measurement at 96 weeks
|
Changes in glucose homeostasis markers and insulin resistance
Time Frame: Measurement at 96 weeks
|
Hemoglobin A1c (HbA1c) in %
|
Measurement at 96 weeks
|
Changes in glucose homeostasis markers and insulin resistance
Time Frame: Measurement at 96 weeks
|
Homeostatic model assessment for insulin resistance (HOMA-IR) (not unit)
|
Measurement at 96 weeks
|
Changes in glucose homeostasis markers and insulin resistance
Time Frame: Measurement at 96 weeks
|
Adponectin in ug/mL
|
Measurement at 96 weeks
|
Changes in glucose homeostasis markers and insulin resistance
Time Frame: Measurement at 96 weeks
|
Retinol binding protein 4 (RBP-4) in ug/mL
|
Measurement at 96 weeks
|
Changes in glucose homeostasis markers and insulin resistance
Time Frame: Measurement at 96 weeks
|
Monocyte chemoattractant protein-1 (MCP-1) in ug/mL
|
Measurement at 96 weeks
|
Changes in glucose homeostasis markers and insulin resistance
Time Frame: Measurement at 96 weeks
|
Plaminogen activator inhibitor-1 (PAI-1) in ug/mL
|
Measurement at 96 weeks
|
Incidence of adverse events
Time Frame: Measurement at 96 weeks
|
Safety and tolerability
|
Measurement at 96 weeks
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Cuadrado A, Orive A, Garcia-Suarez C, Dominguez A, Fernandez-Escalante JC, Crespo J, Pons-Romero F. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg. 2005 Mar;15(3):442-6. doi: 10.1381/0960892053576596.
- Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40. doi: 10.1016/j.cgh.2014.04.014. Epub 2014 Apr 24.
- Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013 Sep;59(3):550-6. doi: 10.1016/j.jhep.2013.04.027. Epub 2013 May 9.
- Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x. Epub 2011 May 30.
- Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006 Oct;45(4):600-6. doi: 10.1016/j.jhep.2006.06.013. Epub 2006 Jul 25.
- Boza C, Riquelme A, Ibanez L, Duarte I, Norero E, Viviani P, Soza A, Fernandez JI, Raddatz A, Guzman S, Arrese M. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005 Sep;15(8):1148-53. doi: 10.1381/0960892055002347.
- Lavin-Alconero L, Fernandez-Lanas T, Iruzubieta-Coz P, Arias-Loste MT, Rodriguez-Duque JC, Rivas C, Cagigal ML, Montalban C, Useros AL, Alvarez-Cancelo A, Garcia-Saiz M, Crespo-Garcia J. Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study). Trials. 2021 Oct 30;22(1):756. doi: 10.1186/s13063-021-05695-7.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TESLA-NASH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-alcoholic Steatohepatitis (NASH)
-
Corcept TherapeuticsRecruitingNon-alcoholic Steatohepatitis (NASH)United States
-
Novartis PharmaceuticalsTerminatedNon-alcoholic Steatohepatitis (NASH)Belgium, Germany, Taiwan, Austria, United States, Spain, Korea, Republic of, Argentina, Australia, Italy, Japan, Singapore, Netherlands, Slovakia, France, Canada, India
-
Immuron Ltd.CompletedNon-alcoholic Steatohepatitis (NASH)United States, Australia, Israel
-
EccogeneRecruiting
-
Guangdong Raynovent Biotech Co., LtdCompletedNon-Alcoholic Steatohepatitis (NASH)China
-
Novartis PharmaceuticalsTerminatedNon-alcoholic Steatohepatitis NASHUnited Kingdom, United States, Australia, New Zealand, Switzerland, Jordan, Georgia, Puerto Rico
-
Hoffmann-La RocheCompletedNon-Alcoholic Steatohepatitis (NASH)France
-
University of ZurichCompletedNon-alcoholic Steatohepatitis (NASH)Switzerland
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingNon-Alcoholic Steatohepatitis (NASH)China
-
AstraZenecaActive, not recruitingNon-alcoholic Steatohepatitis (NASH)United States
Clinical Trials on Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications
-
The Methodist Hospital Research InstituteRecruitingObesity | Endoscopic Sleeve GastroplastyUnited States
-
Cleveland Clinic LondonRecruitingObesity | Diabetes Mellitus, Type 2United Kingdom
-
Radboud University Medical CenterNot yet recruitingDiabetes Mellitus Type 2 in ObeseNetherlands
-
True You Weight LossActive, not recruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingEnd Stage Renal Disease | Kidney Transplantation | Obesity, Morbid | Endoscopic Sleeve GastroplastyItaly
-
True You Weight LossActive, not recruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingLiver Transplantation | Obesity | Bariatric SurgeryItaly
-
Clinique du TrocadéroCompleted
-
Puerta de Hierro University HospitalHospital Universitario Ramon y Cajal; Hospitales Universitarios Virgen del... and other collaboratorsUnknownObesity | Non-Alcoholic Fatty Liver DiseaseSpain
-
Christopher C. Thompson, MD, MScEnrolling by invitationObesity | Abdominal Pain | Weight Loss | Obesity, Morbid | Complication of Surgical Procedure | Weight Gain | Bariatric Surgery Candidate | Complication,Postoperative | Abdominal Obesity | Complication of Treatment | Roux-en-y Anastomosis Site | Ulcer, Gastric | Obesity Associated Disorder | Leak, Anastomotic | Fistula... and other conditionsUnited States